revumenib
syndax pharma
['leukemia', 'sndx-5613']
 i am encouraged by these results, which suggest that sndx-5613 may be an effective oral targeted therapy for patients with an acute leukemia caused by these genetic alterations, says our dr. ghayas issa: #ash22 #endcancer
MD Anderson is a global leader in cancer care, research, education and training, and prevention. Appointments available: 1-877-632-6789